# Bioequivalence (BE) Study Comparing Azithromycin 250 mg Tablet Manufactured in China and in the United States

> **NCT03353480** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 66 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Azithromycin Tablet manufactured in China
- **DRUG:** Azithromycin Tablet manufactured in US

## Key facts

- **NCT ID:** NCT03353480
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-20
- **Primary completion:** 2018-01-29
- **Final completion:** 2018-02-26
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03353480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03353480, "Bioequivalence (BE) Study Comparing Azithromycin 250 mg Tablet Manufactured in China and in the United States". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03353480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*